METASTATIC ADENOCARCINOMA OF PARA-URETHRAL GLAND PRESENTING AS INGUINAL LYMPH NODE AND RECURRENT BULBAR URETHRAL STRICTURE
Adam Jones¹, Samuel Mills¹, Sinthuja Naguleswaran¹, Tom Newton², Mohan Pillai¹

¹Department of Urology, East Lancashire Hospitals Trust
²Department of Radiology, East Lancashire Hospitals Trust

Correspondence: apjones47@doctors.org.uk

Submitted: January 15, 2020. Accepted: February 12, 2020. Published: April 29, 2020.

ABSTRACT
Para-urethral gland carcinoma is a rare urological malignancy that has a male predominance and has an age-adjusted incidence of 1.5–4.3/million. There are various histological subtypes of para-urethral carcinoma, with adenocarcinoma representing only 16.4% of these. Treatment is dependent on site, stage and patient factors. A multimodal approach is often adopted for the treatment of this malignancy. This includes radical surgery based on site of malignancy and there have been various case reports describing the role of adjuvant chemotherapy. However, there is still no agreed recommendation or available evidence for treatment of this infrequently encountered malignancy. The majority of patients present with symptoms of advanced disease and outcomes remain poor. We report a case of para-urethral gland adenocarcinoma presenting as recurrent bulbar urethral stricture and inguinal lymph node metastasis. This case report aims to highlight the rarity of the disease and discuss treatment options for this uncommon urological malignancy.

CASE REPORT
A 62-year-old male presented to primary care with a painless mass in the left inguinal region and voiding lower urinary tract symptoms (LUTS). His past medical history was for optical urethrotomy for bulbar urethral stricture in 2004, bicuspid aortic valve and hypertension. His drug history was for amlodipine. Examination revealed a palpable 2-cm lymph node (LN) in the left inguinal region. The hernial orifices and external genitalia were normal, digital rectal examination (DRE) revealed a benign prostate. Urine dipstick was negative and routine blood tests were sent. The patient was prescribed antibiotics based on LUTS.

The patient re-presented to primary care with ongoing symptoms and perineal pain. There was no tenderness on repeat DRE. The blood samples taken at the initial presentation were all normal with PSA 2.2 ug/L. The primary care physician arranged for urgent computed tomography (CT) of the abdomen and pelvis.

The CT report commented on enlarged LN measuring 11 × 21 mm in the left inguinal region with minor fat stranding. There was no other lymphadenopathy. There was also a thickened bladder wall at 6–7 mm

J Endolum Endourol Vol 3(2):1–4; April 29, 2020.
This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License. © Jones, et al.

e1
but with no focal bladder lesions. The patient was then referred to the hematuria clinic as a two-week wait.

In the hematuria clinic, the patient described severe voiding LUTS and examination found a palpable bladder and confirmed the persistent left inguinal LN. He was investigated with flexible cystoscopy that found complete occlusion of the bulbar urethra due to a necrotic mass. The patient had a suprapubic catheter placed for his retention and added to the urology multidisciplinary team meeting (MDT).

At MDT, the CT was re-reviewed and commented on a 35 × 25 mm soft tissue intramuscular lesion at the left inferolateral aspect of the pubic symphysis and a further lesion measuring 40 × 23 mm at the bulbar urethra. Magnetic resonance imaging (MRI) of the pelvis and CT of the thorax were arranged, in addition to ultrasound-guided biopsy of the LN.

MRI found an abnormal soft tissue lesion with diffusion restriction around the bulbar urethra measuring 45 × 28 mm that infiltrated the apex of the prostate. There was a further 50 × 36 mm lesion at the insertion of the left obturator externus and adductor brevis muscles and a malignant-looking left inguinal LN (Figure 1). CT thorax was reported as indeterminate opacities in the right lower lobe that required follow up imaging but no definite lung metastases.

Trucut biopsy from the inguinal LN was used to obtain histology. Microscopically, they were part lymphoid tissue and part fibrocollagenous tissue infiltrated by adenocarcinoma (Figure 2). Immunostains were strongly positive for CK-7, CDX-2 and TTF-1 within the metastatic adenocarcinoma. Napscin, CK-20, GATA-3, PSA and thyroglobulin were negative. Following MDT discussion, the patient was referred to oncology for consideration of further treatment.

The patient was reviewed by oncology and had a course of palliative radiotherapy arranged to manage his pelvic and perineal pain. Following radiotherapy, he was seen in the clinic to discuss chemotherapy using the gastro-intestinal agent Oxaliplatin and modified De Gramont (5-Fluorouracil and Folinic acid).

DISCUSSION

Para-urethral carcinoma (PUC) is a rare type of malignancy. In the United States, the annual age-adjusted incidence is between 1.5–4.3/million. Swartz et al. reported male predominance to PUC, with men being three times more likely to be affected than females. There are no known causative agents for the development of PUC. Etiological factors include chronic irritation, urethritis, urethral stricture, external beam radiotherapy and human papillomavirus.

PUC can be categorized by histology or location. Swartz et al. reported the histological subtypes of PUC in 1615 patients. This review found transitional cell carcinoma to be most common (55%), followed by

FIG. 1 Coronal T2 weighted images. A – Mass infiltrating tissue into the fat beneath the right inferior pubic ramus, B – Urethra, C – Mass infiltrating into the base of the left corpora cavernosa.
squamous cell carcinoma (21.5%) and adenocarcinoma (16.4%).\textsuperscript{1} The urethra is an uncommon location for adenocarcinoma. The predominant location for adenocarcinoma of the urinary tract is the bladder, where they often demonstrate mucinous or enteric differentiation.\textsuperscript{5} The most common sites for PUC are the bulbomembranous urethra (60%) followed by the penile urethra (30%) and then the prostatic urethra (10%).\textsuperscript{4}

PUC often presents with symptoms of advanced disease (45-57%). Other symptoms include hematuria (62%), extrourethral mass (52%), obstructive voiding (48%), pelvic pain (33%) or fistula (10%).\textsuperscript{2} These cancers metastasize via a direct extension to surrounding structures or through the lymphatic spread.

Anterior PUC primarily spread to the superficial and deep inguinal lymph nodes. Posterior PUC drain to external, obturator and internal iliac lymph nodes. Palpable inguinal nodes are present in 20% of PUC. Hematogenous metastasis is rare as is metastasis to distant organs\textsuperscript{4}.

Investigations for PUC should include cystoscopy and radiological imaging. Cystoscopy allows for direct visualization of urethral tumour and the opportunity to obtain tissue for histology. Dalbagni et al.\textsuperscript{3} reported that an MRI can provide the best anatomical details, tumour extension and lymph involvement.\textsuperscript{4} MRI may also allow visualization of urethral diverticulum that may contain nodular enhancing malignancy in addition to urethral mass\textsuperscript{5}.
There is no agreed management of PUC adenocarcinoma, this is as a result of disease rarity. Treatment would be tailored to the disease stage, location and patient factors. A multimodal approach should, therefore, be adopted.

Surgical excision is the preferred option for PUC. For those patients with superficial PUC located within the anterior urethra, surgical options include transurethral resection or distal urethrectomy. In contrast, proximal or advanced PUC may require radical cystoprostatectomy, urethrectomy, and total penectomy.

The effectiveness of chemotherapy is unknown. Gupta et al. reported a case of urethral adenocarcinoma that was treated with radical surgery and adjuvant chemotherapy. The patient received 5-flurouricil and three cycles of cisplatin, which is commonly used for adenocarcinoma for other organs. At the time of publication, Gupta et al. reported no evidence of recurrent disease at 9 months. In contrast, Gogus et al. reported PUC adenocarcinoma treated with cystectomy and three cycles of methotrexate, vinblastine, epirubicin, and cisplatin but reported recurrence at 5 months and this patient died at 10 months.

CONCLUSION

We report a rare urological malignancy of the male para-urethral glands presenting as recurrent bulbar urethral stricture and inguinal lymph node metastasis. We consider this case to be unique due to the histological subtype being adenocarcinoma. Treatment for this malignancy is not defined as a result of disease rarity. To the author’s best knowledge there is no recommended treatment for this disease and reported treatments are variable. En bloc resection should be considered based on anatomical location and stage. A multimodal approach should be used in advanced cases.

FUNDING AND CONFLICT OF INTEREST

There was no funding received for the production of this manuscript. No potential conflict of interest was reported by the authorship.

REFERENCES

1. Swartz MA, Porter MP, Lin DW et al. Incidence of primary urethral carcinoma in the United States. Urology 2006;68:1164–68.
2. Gheiler EL, Tefilli MV, Tiguert R et al. Management of primary urethral cancer. Urology 1998;52(3):487–93.
3. Dalbagni G, Zhang ZF, Lacombe L et al. Male urethral carcinoma: analysis of treatment outcome. Urology 1999;53:1126–32.
4. Gupta R, Gupta S, Basu S et al. Primary adenocarcinoma of the bulbomembranous urethra in a 33-year-old male patient. J Clin Diagnost Res 2017;11:7–8.
5. Stukalin I, Gao Y, Spaner S et al. Primary adenocarcinoma of bulbomembranous urethra: An exceedingly rare carcinoma in a male patient. Urol Case Rep 2019;26:100941.
6. Venyo A. Clear Cell Adenocarcinoma of the Urethra: Review of the Literature. Int J Surg Oncol 2015;790235
7. GöGUŞ C, Baltaci S, Orhan D et al. Clear cell adenocarcinoma of the male urethra. Int J Urol 2003;10:348–9.